한글목차

유체 생검 시장은 2024년 118억 달러로 평가되며, 2030년에는 227억 2,000만 달러로 연평균 11.50%로 성장할 것으로 예측됩니다.

유체 생검은 비침습적 진단 분야에서 획기적인 발전을 이루었으며, 혈액, 소변 및 기타 체액 내 바이오마커 분석을 통해 질병 상태에 대한 실시간 정보를 제공합니다. 이 기술은 특히 종양학에 큰 영향을 미쳐, 기존 조직 생검 없이도 조기 암 발견, 치료 반응 모니터링, 질병 진행 추적이 가능합니다, 유병률 증가, 정밀 의학 도입 확대, 그리고 차세대 시퀀싱 및 디지털 PCR과 같은 기술 발전은 시장 성장을 가속화하고 있습니다. 또한, 산전 검사, 감염성 질환 탐지, 유전 질환 진단에도 유체 생검을 활용하는 방안이 모색되고 있습니다. 비용, 규제의 복잡성, 임상적 표준화 등의 어려움에도 불구하고, 최소 침습성, 광범위한 진단 적용, 개인화된 치료 접근 방식을 통해 환자 치료를 개선할 수 있는 능력 덕분에 시장이 급속히 확대되고 있습니다.

시장 촉진요인

전 세계 암 발병률 증가

주요 시장 과제

제한적 임상 검증

주요 시장 동향

AI 및 머신러닝과의 통합

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 유체 생검 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 적응증별(폐암, 유방암, 대장암, 기타)
  • 유형별(순환종양세포, 순환 종양 DNA, 유리 DNA)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 유체 생검 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 유체 생검 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 유체 생검 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 유체 생검 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 유체 생검 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병

제13장 PESTEL 분석

제14장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 능력
• 고객의 능력
• 대체품의 위협

제15장 세계의 유체 생검 시장 : SWOT 분석

제16장 경쟁 구도

• Bio-Rad Laboratories
• Guardant Health Inc.
• Illumina, Inc.
• Qiagen NV
• Laboratory Corporation of America Holdings
• F. Hoffmann-La Roche AG
• Thermo Fisher Scientific Inc.
• Johnson & Johnso
• Biocept Inc.
• Bio-Rad Laboratories, Inc.

제17장 전략적 제안

제18장 조사 회사 소개 및 면책사항

영문목차

The Fluid Biopsy Market was valued at USD 11.80 billion in 2024 and is projected to reach USD 22.72 billion by 2030, growing at a CAGR of 11.50%. Fluid biopsy represents a significant advancement in non-invasive diagnostics, offering real-time insights into disease status through the analysis of biomarkers in blood, urine, and other body fluids. This technique is particularly impactful in oncology, enabling early cancer detection, monitoring of treatment response, and tracking of disease progression without the need for traditional tissue biopsies. The rise in cancer prevalence, growing adoption of precision medicine, and technological progress-such as next-generation sequencing and digital PCR-are accelerating market growth. Fluid biopsy is also being explored for use in prenatal testing, infectious disease detection, and genetic disorder diagnosis. Despite challenges including cost, regulatory complexity, and clinical standardization, the market is expanding rapidly due to its minimally invasive nature, broad diagnostic applications, and ability to improve patient care through personalized treatment approaches.

Key Market Drivers

Rising Global Cancer Incidence

The global increase in cancer prevalence is a major factor driving the growth of the fluid biopsy market. With approximately 20 million new cancer cases and 9.7 million related deaths recorded in 2022, and 53.5 million individuals living within five years of a diagnosis, there is a rising need for efficient, non-invasive diagnostic tools. This demand is especially pronounced in aging populations-by 2040, nearly 19.2% of the global population is expected to be over 60, a group disproportionately affected by cancer. Traditional tissue biopsies can be invasive and difficult for certain patients. Fluid biopsy offers a more accessible solution, allowing for early detection through circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs). Furthermore, it supports continuous monitoring, providing insights into disease recurrence and treatment effectiveness. With cancer rates rising globally, fluid biopsy is becoming essential for enhancing early intervention and long-term management, making it a key pillar of modern oncology care.

Key Market Challenges

Limited Clinical Validation

A major challenge for the global fluid biopsy market is the limited clinical validation of its diagnostic technologies. Although fluid biopsy shows great potential, especially in cancer detection and monitoring, many of its assays are still undergoing development and require extensive clinical trials to confirm their sensitivity, specificity, and overall reliability. Without well-established clinical data, healthcare providers may be hesitant to adopt these tests, and regulatory agencies may delay approval. The lack of standardized protocols across institutions also adds complexity. These factors can restrict integration into routine clinical practice. Overcoming this barrier will require significant investments in collaborative research, larger-scale validation studies, and regulatory engagement. Building strong clinical evidence is essential to gaining trust from both physicians and patients and ensuring broader adoption of fluid biopsy technologies in the diagnostic landscape.

Key Market Trends

Integration with AI and Machine Learning

The integration of AI and machine learning is a transformative trend in the fluid biopsy market. These technologies are revolutionizing data analysis by enabling rapid, accurate interpretation of complex biomarker data derived from liquid samples. AI algorithms can detect subtle patterns and correlations that may be missed through traditional analysis, enhancing diagnostic precision and expanding clinical utility. These tools are especially beneficial for early cancer detection, treatment response evaluation, and identifying actionable mutations for targeted therapy. As AI continues to evolve, it enables deeper insights into disease progression and therapeutic outcomes, empowering personalized treatment plans. Additionally, AI can facilitate the discovery of new biomarkers, supporting innovation in diagnostics beyond oncology. By streamlining data processing and improving predictive accuracy, AI integration is solidifying fluid biopsy's role in advancing precision medicine and transforming patient care on a global scale.

Key Market Players

• Bio-Rad Laboratories
• Guardant Health Inc.
• Illumina, Inc.
• Qiagen NV
• Laboratory Corporation of America Holdings
• F. Hoffmann-La Roche AG
• Thermo Fisher Scientific Inc.
• Johnson & Johnson
• Biocept Inc.
• Bio-Rad Laboratories, Inc.

Report Scope:

In this report, the Global Fluid Biopsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Fluid Biopsy Market, By Indication:

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Other

Fluid Biopsy Market, By Type:

• Circulating Tumor Cells
• Circulating Tumor DNA
• Cell-free DNA

Fluid Biopsy Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Fluid Biopsy Market.

Available Customizations:

Global Fluid Biopsy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional Market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Fluid Biopsy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Other)
  • 5.2.2. By Type (Circulating Tumor Cells, Circulating Tumor DNA, Cell-free DNA)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Fluid Biopsy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication
  • 6.2.2. By Type
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Fluid Biopsy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By Type
  • 6.3.2. Canada Fluid Biopsy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By Type
  • 6.3.3. Mexico Fluid Biopsy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By Type

7. Europe Fluid Biopsy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication
  • 7.2.2. By Type
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Fluid Biopsy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By Type
  • 7.3.2. United Kingdom Fluid Biopsy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By Type
  • 7.3.3. Italy Fluid Biopsy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By Type
  • 7.3.4. France Fluid Biopsy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
      • 7.3.4.2.2. By Type
  • 7.3.5. Spain Fluid Biopsy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication
      • 7.3.5.2.2. By Type

8. Asia-Pacific Fluid Biopsy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By Type
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Fluid Biopsy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By Type
  • 8.3.2. India Fluid Biopsy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By Type
  • 8.3.3. Japan Fluid Biopsy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By Type
  • 8.3.4. South Korea Fluid Biopsy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Indication
      • 8.3.4.2.2. By Type
  • 8.3.5. Australia Fluid Biopsy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Indication
      • 8.3.5.2.2. By Type

9. South America Fluid Biopsy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By Type
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Fluid Biopsy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By Type
  • 9.3.2. Argentina Fluid Biopsy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By Type
  • 9.3.3. Colombia Fluid Biopsy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By Type

10. Middle East and Africa Fluid Biopsy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication
  • 10.2.2. By Type
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Fluid Biopsy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By Type
  • 10.3.2. Saudi Arabia Fluid Biopsy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By Type
  • 10.3.3. UAE Fluid Biopsy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Global Fluid Biopsy Market: SWOT Analysis

16. Competitive Landscape

• 16.1. Bio-Rad Laboratories
  • 16.1.1. Business Overview
  • 16.1.2. Product & Service Offerings
  • 16.1.3. Recent Developments
  • 16.1.4. Financials (If Listed)
  • 16.1.5. Key Personnel
  • 16.1.6. SWOT Analysis
• 16.2. Guardant Health Inc.
• 16.3. Illumina, Inc.
• 16.4. Qiagen NV
• 16.5. Laboratory Corporation of America Holdings
• 16.6. F. Hoffmann-La Roche AG
• 16.7. Thermo Fisher Scientific Inc.
• 16.8. Johnson & Johnso
• 16.9. Biocept Inc.
• 16.10.Bio-Rad Laboratories, Inc.

17. Strategic Recommendations

18. About Us & Disclaimer